Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -1.96 | $0 | -$3M |
| 2025 Q3 | -1.41 | $0 | -$1M |
| 2025 Q2 | -0.06 | $0 | -$912 |
| 2025 Q1 | -0.06 | $0 | -$912 |
| 2024 Q4 | -36.30 | $0 | -$810,000 |
| 2024 Q3 | -36.30 | $0 | -$405 |
| 2024 Q2 |
| -29.95 |
| $0 |
| -$337,000 |
| 2024 Q1 | -29.95 | $0 | -$169 |